Literature DB >> 10198197

The human phospholamban gene: structure and expression.

C F McTiernan1, C S Frye, B H Lemster, E A Kinder, M L Ogletree-Hughes, C S Moravec, A M Feldman.   

Abstract

Phospholamban, through modulation of sarcoplasmic reticulum calcium-ATPase activity, is a key regulator of cardiac diastolic function. Alterations in phospholamban expression may define parameters of muscle relaxation. In experimental animals, phospholamban is differentially expressed in various striated and smooth muscles, and within the four chambers of the heart. Decreased phospholamban expression within the heart during heart failure has also been observed. Furthermore, regulatory elements of mammalian phospholamban genes remain poorly defined. To extend these studies to humans, we (1) characterized phospholamban expression in various human organs, (2) isolated genomic clones encoding the human phospholamban gene, and (3) prepared human phospholamban promoter/luciferase reporter constructs and performed transient transfection assays to begin identification of regulatory elements. We observed that human ventricle and quadriceps displayed high levels of phospholamban transcripts and proteins, with markedly lower expression observed in smooth muscles, while the right atria also expressed low levels of phospholamban. The human phospholamban gene structure closely resembles that reported for chicken, rabbit, rat, and mouse. Comparison of the human to other mammalian phospholamban genes indicates a marked conservation of sequence for at least 217 bp upstream of the transcription start site, which contains conserved motifs for GATA, CP1/NFY, M-CAT-like, and E-box elements. Transient transfection assays with a series of plasmids containing deleted 5' flanking regions (between -2530 and -66 through +85) showed that sequences between -169 and the CP1-box at -93 were required for maximal promoter activity in neonatal rat cardiomyocytes. Activity of these reporters in HeLa cells was markedly lower than that observed in rat cardiomyocytes, suggesting at least a partial tissue selectivity of these reporter constructs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198197     DOI: 10.1006/jmcc.1998.0904

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

1.  Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications.

Authors:  Madesh Belakavadi; Jason Saunders; Noah Weisleder; Preethi S Raghava; Joseph D Fondell
Journal:  Endocrinology       Date:  2010-04-14       Impact factor: 4.736

2.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Authors:  Kobra Haghighi; Fotis Kolokathis; Anthony O Gramolini; Jason R Waggoner; Luke Pater; Roy A Lynch; Guo-Chang Fan; Dimitris Tsiapras; Rohan R Parekh; Gerald W Dorn; David H MacLennan; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  HRC is a direct transcriptional target of MEF2 during cardiac, skeletal, and arterial smooth muscle development in vivo.

Authors:  Joshua P Anderson; Evdokia Dodou; Analeah B Heidt; Sarah J De Val; Eric J Jaehnig; Stephanie B Greene; Eric N Olson; Brian L Black
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

4.  Myocyte-specific M-CAT and MEF-1 elements regulate G-protein gamma 3 gene (gamma3) expression in cardiac myocytes.

Authors:  Charlene McWhinney; Janet D Robishaw
Journal:  DNA Cell Biol       Date:  2008-07       Impact factor: 3.311

5.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.

Authors:  Kobra Haghighi; Guoli Chen; Yoji Sato; Guo-Chang Fan; Suiwen He; Fotis Kolokathis; Luke Pater; Ioannis Paraskevaidis; W Keith Jones; Gerald W Dorn; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

7.  Cardiac Gene Expression Knockdown Using Small Inhibitory RNA-Loaded Microbubbles and Ultrasound.

Authors:  Jonathan A Kopechek; Andrew R Carson; Charles F McTiernan; Xucai Chen; Edwin C Klein; Flordeliza S Villanueva
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

Review 8.  Current Landscape of Heart Failure Gene Therapy.

Authors:  Jake M Kieserman; Valerie D Myers; Praveen Dubey; Joseph Y Cheung; Arthur M Feldman
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

9.  Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers.

Authors:  Daniel Koch; Alexander Alexandrovich; Florian Funk; Ay Lin Kho; Joachim P Schmitt; Mathias Gautel
Journal:  Cell Rep       Date:  2021-07-27       Impact factor: 9.995

10.  Temporal and morphological impact of pressure overload in transgenic FHC mice.

Authors:  Hao Chen; Hyosook Hwang; Laurel A K McKee; Jessica N Perez; Jessica A Regan; Eleni Constantopoulos; Bonnie Lafleur; John P Konhilas
Journal:  Front Physiol       Date:  2013-08-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.